Results 31 to 40 of about 3,164,975 (245)

Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs. [PDF]

PLoS ONE, 2014
OBJECTIVES: To assess HCV viremia levels just before, during and one year after anti-HCV seroconversion in people who inject drugs (PWID). METHODS: PWID enrolling into a needle exchange program in Malmö, Sweden, 1997-2005 constituted the source ...
Marianne Alanko Blomé, Per Björkman, Vilma Molnegren, Peter Höglund, Anders Widell   +4 more
doaj   +1 more source

The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection

Jundishapur Journal of Microbiology, 2015
Background: Hepatitis C Virus (HCV) infection is diagnosed by antibody and RNA based methods. Patients with anti-HCV sample rate/cutoff rate (S/CO) ratios > 1 are reported as anti-HCV positive.
Fahimeh Ranjbar Kermani, Z. Sharifi, Fereshteh Ferdowsian, Z. Paz, Farzaneh Tavassoli   +4 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. [PDF]

PLoS ONE, 2013
We reported previously that Artemisinin (ART), a widely used anti-malarial drug, is an inhibitor of in vitro HCV subgenomic replicon replication. We here demonstrate that ART exerts its antiviral activity also in hepatoma cells infected with full length ...
Susan Obeid, Jo Alen, Van Hung Nguyen, Van Cuong Pham, Philip Meuleman, Christophe Pannecouque, Thanh Nguyen Le, Johan Neyts, Wim Dehaen, Jan Paeshuyse   +9 more
doaj   +1 more source

Analysis of reactive HCV results detected by current blood screening strategy

Zhongguo shuxue zazhi, 2022
Objective To assess the status of HCV infection by analyzing the results of anti-HCV reactive blood samples detected by the current blood testing strategy, and discuss the viability of classified management of reactive blood donors.
ZhengMin LIU, Rui WANG, Jin GUO, Jing ZHANG, Yi ZHA, Hongwei GE, Ling LI   +6 more
doaj   +1 more source

MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3.

Virology, 2014
MiR-221 was reported to be upregulated and play roles in tumorigenesis of hepatitis C virus (HCV) associated hepatocellular carcinoma (HCC). However, the role of miR-221 in HCV infection remains unknown.
Gang Xu, Fang Yang, Cuiling Ding, Jing Wang, P. Zhao, Wen Wang, H. Ren   +6 more
semanticscholar   +1 more source

The Utility of ANTI-HCV S/CO Ratio, HCV-RNA and ALT Test in Predicting Viremia in ANTI-HCV Positive Patients [PDF]

Türk Biyokimya Dergisi, 2007
Hepatitis C Virus (HCV) infection is frequently diagnosed by detection of antibodyagainst the HCV (Anti-HCV). The seropositivity of anti-HCV could reflect chronicinfectious status and/or previous infection.
Tuğrul Himmetoğlu, Hüseyin Şimşek, Aygül Türkmen, Doğan Cengiz, Gülsevim Saydam, Mevhibe Balk   +5 more
doaj  

Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies

PLoS ONE, 2014
Background The development of a risk assessment tool for long-term hepatocellular carcinoma risk would be helpful in identifying high-risk patients and providing information of clinical consultation.
Mei‐Hsuan Lee, Sheng-Nan Lu, Yong Yuan, Hwai I. Yang, C. Jen, S. You, Li‐Yu Wang, G. L’italien, Chien-Jen Chen   +8 more
semanticscholar   +1 more source

Hepatitis C testing and status among opioid substitution treatment clients in New South Wales

Australian and New Zealand Journal of Public Health, 2014
Background: In Australia about half of the people who inject drugs (PWID) are hepatitis C (HCV) antibody positive (anti‐HCV+). The prevalence among opioid substitution treatment (OST) clients specifically is unclear, despite OST clinics being a potential
Fiona L. Shand, Carolyn Day, William Rawlinson, Louisa Degenhardt, Nicholas G. Martin, Elliot C. Nelson   +5 more
doaj   +1 more source

Performance characteristics of a combined hepatitis C virus core antigen and anti–hepatitis C virus antibody test in different patient groups

Kaohsiung Journal of Medical Sciences, 2011
We evaluated the performance of a hepatitis C virus (HCV) antigen/antibody combination test [Murex HCV Antigen/Antibody Combination Test (Murex Ag/Ab test)] by comparing it with the current third-generation HCV antibody enzyme immunoassay (anti-HCV).
Jeng-Fu Yang, Ya-Yun Lin, Meng-Hsuan Hsieh, Chiu-Hung Tsai, Shu-Fen Liu, Ming-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, Wen-Yi Lin, Zu-Yau Lin, Shinn-Chern Chen, Wan-Long Chuang   +11 more
doaj   +1 more source